About this Research Topic
Targeted immunotherapies have been clinically tested against leukemia, melanoma, pancreatic, prostate, breast, lung, and colon cancers. While there have been several failed clinical studies, there have been notable successes (such as antigen-pulsed activated dendritic cells in prostate cancer) and important insights have been gained. One key insight is the ability of cancers to selectively turn off the immune system using “immune checkpoints”. Checkpoint inhibitors, such as antibodies to PD-1, PD-L1 or CTLA4, show pharmacologic activity in those cancers which have elicited an immune response often regress. The pharmacology of targeted immunotherapies relies on their ability to induce a cancer-specific immune response. This suggests that combination of targeted immunotherapies with checkpoint inhibitors might show synergistic pharmacologic activity in inducing effective anti-cancer immune responses.
The purpose of this Research Topic will be to probe deeply into the data available and chart the path forward for targeted immunotherapies. Article types will include Original Research articles, Reviews and Opinion/Hypothesis papers. Specific areas will include human clinical data (clinical trials) and pre-clinical/animal studies. Sub-topics for both clinical and pre-clinical categories will include cell-based immunotherapies, neoantigen approaches, tumor associated antigens, DNA immunogens, and other antigen-specific approaches.
Topic Editor, William Williams, is the president and CEO of BriaCell, which is developing a targeted immunotherapy for breast cancer. This includes raising money to support research and clinical programs and applying for grants. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords: Cancer, Immunotherapy, Oncology, Antigen, Vaccine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.